of the Secretary at 202–205–2000. General information concerning the Commission may also be obtained by accessing its internet server (*https://www.usitc.gov*). The public record for this matter may be viewed on the Commission's electronic docket (EDIS) at *https://edis.usitc.gov.*

Authority: This investigation is being closed under authority of section 701(c)(1) & (5) of the Tariff Act of 1930 (19 U.S.C. 1671(c)(1) & (5)). This notice is published pursuant to section 201.10 of the Commission's rules (19 CFR 201.10).

By order of the Commission.

Issued: May 18, 2026.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2026–10080 Filed 5–19–26; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1717]

Bulk Manufacturer of Controlled Substances Application: Organix Chemistry Solutions LLC

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Organix Chemistry Solutions, LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before July 20, 2026. Such persons may also file a written request for a hearing on the application on or before July 20, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on April 28, 2026, Organix Chemistry Solutions, LLC, 32 Cabot Road, Woburn, Massachusetts 01801–1004, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Methamphetamine	1105	II

The company plans to synthesize the listed controlled substance for distribution to its customers. No other activity for this drug code is authorized for this registration.

Thomas Prevoznik,

Deputy Assistant Administrator.

[FR Doc. 2026–10087 Filed 5–19–26; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1716]

Importer of Controlled Substances Application: Amneal Pharmaceuticals, LLC

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Amneal Pharmaceuticals, LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before June 22, 2026. Such persons may also file a written request for a hearing on the application on or before June 22, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on May 4, 2026, Amneal Pharmaceuticals, LLC, 47 Colonial Drive, Piscataway, New Jersey 08854, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Remifentanil	9739	II

The company plans to import the above listed controlled substance as finished unit formulations for internal development and research purposes only. No other activity for this drug code is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration- approved or non approved finished dosage forms for commercial sale.

Thomas Prevoznik,

Deputy Assistant Administrator.

[FR Doc. 2026–10089 Filed 5–19–26; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–372]

Exempt Chemical Preparations Under the Controlled Substances Act

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Order with opportunity for comment.

SUMMARY: The applications for exempt chemical preparations received by the Drug Enforcement Administration between July 1, 2025, and March 31, 2026, as listed below, were accepted for filing and have been approved or denied as indicated. This publication addresses preparations through March 31, 2026, that were not included in previous **Federal Register** notices, and it does not affect preparations that have been previously published. This order also corrects the listing of several preparations that were published in the **Federal Register** notice on March 20, 2026.

DATES: Comments must be submitted electronically or postmarked on or before July 20, 2026.

ADDRESSES: Interested persons may file written comments on this order in accordance with 21 CFR 1308.23(e). The electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period. To ensure proper handling of comments, please reference ''Docket No. DEA–372'' on all correspondence, including any attachments.

- *Electronic comments:* The Drug Enforcement Administration (DEA) encourages that all comments be submitted through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or to attach a file for lengthier comments. Please go to *http://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon completion of your submission, you will receive a Comment Tracking Number for your comment. Please be aware that submitted comments are not instantaneously available for public view on *Regulations.gov*. If you have received a comment tracking number, your comment has been successfully submitted and there is no need to resubmit the same comment.
- *Paper comments:* Paper comments that duplicate the electronic submission are not necessary and are discouraged. Should you wish to mail a comment *in lieu of* an electronic comment, it should be sent via regular or express mail to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.
- *Paperwork Reduction Act Comments:* All comments concerning collections of information under the Paperwork Reduction Act must be submitted to the Office of Information and Regulatory Affairs, OMB, Attention: Desk Officer for DOJ, Washington, DC 20503. Please state that your comment refers to Docket No. DEA–1189.

FOR FURTHER INFORMATION CONTACT: Terrence L. Boos, Ph.D., Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152; Telephone: (571) 362–8201.

SUPPLEMENTARY INFORMATION:

Posting of Public Comments

Please note that all comments received in response to this docket are considered part of the public record. The Drug Enforcement Administration (DEA) will make comments available for public inspection online at *http://www.regulations.gov.* Such information includes personal or business identifiers (such as name, address, state or Federal identifiers, etc.) voluntarily submitted by the commenter. Generally, all information voluntarily submitted by the commenter, unless clearly marked as Confidential Information in the method described below, will be publicly posted. Comments may be submitted anonymously. The Freedom of Information Act applies to all comments received.

Commenters submitting comments which include personal identifying information (PII), confidential, or proprietary business information that the commenter does not want made publicly available should submit two copies of the comment. One copy must be marked ''CONTAINS CONFIDENTIAL INFORMATION'' and should clearly identify all PII or business information the commenter does not want to be made publicly available, including any supplemental materials. DEA will review this copy, including the claimed PII and confidential business information, in its consideration of comments. The second copy should be marked ''TO BE PUBLICLY POSTED'' and must have all claimed confidential PII and business information already redacted. DEA will post only the redacted comment on *http://www.regulations.gov* for public inspection.

For easy reference, an electronic copy of this document and supplemental information to this proposed scheduling action are available at *http://www.regulations.gov.*

Legal Authority

Section 201 of the Controlled Substances Act (CSA) (21 U.S.C. 811) authorizes the Attorney General, by regulation, to exempt from certain provisions of the CSA certain compounds, mixtures, or preparations containing a controlled substance, if he finds that such compounds, mixtures, or preparations meet the requirements detailed in 21 U.S.C. 811(g)(3)(B).[1] DEA regulations at 21 CFR 1308.23 and 1308.24 further detail the criteria by which the DEA Assistant Administrator may exempt a chemical preparation or mixture from certain provisions of the CSA. The Assistant Administrator may, pursuant to 21 CFR 1308.23(f), modify or revoke the criteria by which exemptions are granted and modify the scope of exemptions at any time.

Exempt Chemical Preparation Applications Submitted Between July 1, 2025, and March 31, 2026

DEA received applications between July 1, 2025, and March 31, 2026, requesting exempt chemical preparation status detailed in 21 CFR 1308.23. This publication addresses preparations through March 31, 2026, that were not included in previous **Federal Register** notices, and it does not affect preparations that have been previously published. Additionally, this order corrects the listing of several preparations that were incorrectly listed in the previous **Federal Register** notice dated, March 20, 2026. The company name, product name, and/or form have been corrected. Pursuant to the criteria stated in 21 U.S.C. 811(g)(3)(B) and in 21 CFR 1308.23, the Assistant Administrator has found that each of the compounds, mixtures, and preparations described in Chart I below is intended for laboratory, industrial, educational, or special research purposes and not for general administration to a human being or animal and either: (1) contains no narcotic controlled substance and is packaged in such a form or concentration that the packaged quantity does not present any significant potential for abuse; or (2) contains either a narcotic or non-narcotic controlled substance and one or more adulterating or denaturing agents in such a manner, combination, quantity, proportion, or concentration that the preparation or mixture does not present any potential for abuse and, if the preparation or mixture contains a narcotic controlled substance, is formulated in such a manner that it incorporates methods of denaturing or other means so that the preparation or mixture is not liable to be abused or have ill effects, if abused, and so that

[1] This authority has been delegated from the Attorney General to the DEA Administrator by 28 CFR 0.100, and subsequently redelegated to the Deputy Assistant Administrator pursuant to 28 CFR 0.104 and Section 7 of the appendix to subpart R of part 0.

the narcotic substance cannot in practice be removed.

Accordingly, pursuant to 21 U.S.C. 811(g)(3)(B), 21 CFR 1308.23, and 21 CFR 1308.24, the Assistant Administrator has determined that each of the chemical preparations or mixtures generally described in Chart I below and specifically described in the application materials received by DEA is exempt, to the extent described in 21 CFR 1308.24, from application of sections 302, 303, 305, 306, 307, 308, 309, 1002, 1003, and 1004 (21 U.S.C. 822–823, 825–829, and 952–954) of the CSA, and 21 CFR 1301.74, as of the date that was provided in the approval letters to the individual requesters.

Scope of Approval

The exemptions are applicable only to the precise preparation or mixture described in the application submitted to DEA in the form(s) listed in this order and only for those above-mentioned sections of the CSA and the CFR. In accordance with 21 CFR 1308.24(h), any change in the quantitative or qualitative composition of the preparation or mixture, or change in the trade name or other designation of the preparation or mixture after the date of application requires a new application. The requirements set forth in 21 CFR 1308.24(b)–(e) apply to the exempted materials. In accordance with 21 CFR 1308.24(g), DEA may prescribe requirements other than those set forth in 21 CFR 1308.24(b)–(e) on a case-by-case basis for materials exempted in bulk quantities. Accordingly, in order to limit opportunities for diversion from the larger bulk quantities, DEA has determined that each of the exempted bulk products listed in this order may only be used in-house by the manufacturer, and may not be distributed for any purpose, or transported to other facilities.

Additional exempt chemical preparation requests received between January 1, 2026, and March 31, 2026, and not otherwise referenced in this order or in prior orders, may remain under consideration until DEA receives additional information required, pursuant to 21 CFR 1308.23(d), as detailed in separate correspondence to individual requesters. DEA's order on such requests will be communicated to the public in a future **Federal Register** publication.

DEA also notes that these exemptions are limited to exemption from only those sections of the CSA and the CFR that are specifically identified in 21 CFR 1308.24(a). All other requirements of the CSA and the CFR apply, including registration as an importer as required by 21 U.S.C. 957.

CHART I

Supplier name	Product name	Form	Application date
Cayman Chemical Company	Alprazolam (CRM) 1 mg/mL in methanol	Glass ampule: 2 mL	3/17/2026
Cayman Chemical Company	Alprazolam-d5 (CRM) 1 mg/mL in methanol	Glass ampule: 2 mL	3/17/2026
Cayman Chemical Company	Clonazepam (CRM) 1 mg/mL in acetonitrile	Glass ampule: 2 mL	3/17/2026
Cayman Chemical Company	Custom 13-Phytocannabinoid Mixture (CRM)—AIT (500 µg/mL each in Acetonitrile).	Glass ampule: 1 mL	1/19/2026
Cayman Chemical Company	Custom Phytocannabinoid Mixture 3, 1 mg/mL ea in acetonitrile	Glass ampule: 1 mL	1/29/2026
Cayman Chemical Company	Flunitrazepam (CRM) 1 mg/mL in acetonitrile	Glass ampule: 2 mL	3/17/2026
Cayman Chemical Company	Flunitrazepam (CRM) 1 mg/mL in methanol	Glass ampule: 2 mL	3/17/2026
Cayman Chemical Company	Lorazepam (CRM) 1 mg/mL in acetonitrile	Glass ampule: 2 mL	3/17/2026
Cayman Chemical Company	Lorazepam-13C2-d4 (CRM) 0.1 mg/mL in acetonitrile	Glass ampule: 2 mL	3/17/2026
Cayman Chemical Company	Lorazepam-13C2-d4 (CRM) 1 mg/mL in acetonitrile	Glass ampule: 2 mL	3/17/2026
Cayman Chemical Company	Lorazepam-d4 (CRM) 1 mg/mL in acetonitrile	Glass ampule: 2 mL	3/17/2026
Cayman Chemical Company	Methylmethcathinone Isomer Mixture 1 mg/mL in methanol	Glass ampule: 1 mL	10/1/2025
Cayman Chemical Company	Methylmethcathinone Isomer Mixture 100 µg/mL in methanol	Glass ampule: 1 mL	10/1/2025
Cayman Chemical Company	Phytocannabinoid Mixture 3 (CRM) 1 mg/mL ea in acetonitrile	Glass ampule: 1 mL	1/29/2026
Cayman Chemical Company	Δ8-THC-C9 (CRM) 1 mg/mL in acetonitrile	Glass ampule: 1 mL	10/1/2025
Cayman Chemical Company	Δ9-THC (CRM) 1 mg/mL in acetonitrile	Glass ampule: 1 mL	1/29/2026
Cayman Chemical Company	Δ9-THC (CRM) 100 µg/mL in acetonitrile	Glass ampule: 1 mL	1/29/2026
Cayman Chemical Company	Δ9-THCA-B (CRM) 1 mg/mL in acetonitrile	Glass ampule: 1 mL	10/1/2025
Cayman Chemical Company	Δ9-THCA-B (CRM) 1 mg/mL in methanol	Glass ampule: 1 mL	10/1/2025
Cayman Chemical Company	Δ9-THCA-B (CRM) 100 µg/mL in acetonitrile	Glass ampule: 1 mL	10/1/2025
Cayman Chemical Company	Δ9-THCA-B (CRM) 100 µg/mL in methanol	Glass ampule: 1 mL	10/1/2025
Cayman Chemical Company	Δ9-THCB Butanoate (CRM) 1 mg/mL in acetonitrile	Glass ampule: 1 mL	10/1/2025
Cayman Chemical Company	Δ9-THC-C9 (CRM) 1 mg/mL in acetonitrile	Glass ampule: 1 mL	10/1/2025
Cayman Chemical Company	Δ9-THC-d9 (CRM) 1 mg/mL in acetonitrile	Glass ampule: 1 mL	1/29/2026
Cayman Chemical Company	Δ9-THC-d9 (CRM) 100 µg/mL in acetonitrile	Glass ampule: 1 mL	1/29/2026
Cerilliant Corporation	Buprenorphine Related Compound A 1.0 mg/mL solvent	Glass ampule: 2 mL	1/29/2026
CPI International	Custom Cannabinoid mixture 3–0539 1000 ug/mL, 0.5 mL (ISO 17034) Z–G34–140539–01.	Glass ampule: 0.5 mL	2/4/2026
CPI International	Custom Cannabinoid mixture 7–0538 1000 ug/mL, 0.5 mL (ISO 17034) Z–G34–140538–01.	Glass ampule: 0.5 mL	2/4/2026
LGC—Dr. Ehrenstorfer	Custom 1-Methylamino-1-(3,4-methylenedioxyphenyl)-propane Hydrochloride 10 ug/mL in Acetonitrile.	Amber ampule: 1 mL	9/24/2025
LGC—Dr. Ehrenstorfer	Custom Hormone Mixture 17762 100 ug/mL in Methanol DRE–Q60017762.	Glass ampule: 5 mL	2/17/2026
LGC—Dr. Ehrenstorfer	Custom p-Hydroxycocaine Hydrochloride 100 ug/mL in Acetonitrile DRE–Q60020132.	Pack: 5 x 1 mL glass ampules	3/4/2026
LGC-Lipomed	4-Methylmethcathinone HCl (Mephedrone), 1mg/ml in Methanol (as free base).	Glass ampule: 1 ml	8/5/2025
LGC-Lipomed	4-MethylmethcathinoneD3 HCl (Mephedrone) 0.1mg/ml in Methanol (as free base).	Glass Ampule: 1 ml	10/13/2025
LGC-Lipomed	Phenobarbital-D5 (side chain), 0.1 mg/ml in Methanol Prod No: LPM–PHB–1720–FA–0.1LM.	Glass Ampule: 1 ml	8/12/2025
Lin-Zhi International	FEN Validation Sample Set 1	Set: 3 tubes, 10 ml each	7/18/2025
Lin-Zhi International	FEN Validation Sample Set 2	Set: 9 tubes, 10 ml each	7/18/2025
Lin-Zhi International	FEN Validation Sample Set 3	Set: 4 tubes, 30 ml each	7/18/2025
Lin-Zhi International	FEN Validation Sample Set 4	Set: 2 tubes,10 ml each	7/18/2025
Lin-Zhi International	FEN Validation Sample Set 5	Set: 52 vials, 1 ml each	7/18/2025
Lin-Zhi International	LZI Barbiturate Calibrator (Oral Fluid) Secobarbital, Cutoff Calibrator Ref# S0143b.	Dropper bottle: 5 mL	2/26/2026

CHART I—Continued

Supplier name	Product name	Form	Application date
Lin-Zhi International	LZI Barbiturate Calibrator (Oral Fluid) Secobarbital, High Calibrator Ref# S0145b.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Barbiturate Calibrator/Control (Oral Fluid) Secobarbital, Intermediate Calibrator/Level 2 Control Ref# S0148b.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Barbiturate Calibrator/Control (Oral Fluid) Secobarbital, Low Calibrator/Level 1 Control Ref# S0147b.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Benzodiazepine Calibrator (Oral Fluid) Oxazepam, Cutoff Calibrator Ref# S0133c.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Benzodiazepine Calibrator (Oral Fluid) Oxazepam, High Calibrator Ref# S0135c.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Benzodiazepine Calibrator/Control (Oral Fluid) Oxazepam, Intermediate Calibrator/Level 2 Control Ref# S0138c.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Benzodiazepine Calibrator/Control (Oral Fluid) Oxazepam, Low Calibrator/Level 1 Control Ref# S0137c.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Cocaine Metabolite Calibrator (Oral Fluid) Benzoylecgonine, Cutoff Calibrator Ref# S0034d.	Dropper bottle: 5 mL	2/27/2026
Lin-Zhi International	LZI Cocaine Metabolite Calibrator (Oral Fluid) Benzoylecgonine, High Calibrator Ref# S0036d.	Dropper bottle: 5 mL	2/27/2026
Lin-Zhi International	LZI Cocaine Metabolite Calibrator (Oral Fluid) Benzoylecgonine, Intermediate Calibrator Ref# S0035d.	Dropper bottle: 5 mL	2/27/2026
Lin-Zhi International	LZI Cocaine Metabolite Calibrator (Oral Fluid) Benzoylecgonine, Low Calibrator Ref# S0033d.	Dropper bottle: 5 mL	2/27/2026
Lin-Zhi International	LZI Cocaine Metabolite Control (Oral Fluid) Benzoylecgonine, Level 1 Control Ref# S0037d.	Dropper bottle: 5 mL	2/27/2026
Lin-Zhi International	LZI Cocaine Metabolite Control (Oral Fluid) Benzoylecgonine, Level 2 Control Ref# S0038d.	Dropper bottle: 5 mL	2/27/2026
Lin-Zhi International	LZI Fentanyl Calibrator (Urine) Fentanyl, Cutoff Calibrator Ref# 0993	Dropper bottle: 5 mL	2/27/2026
Lin-Zhi International	LZI Fentanyl Calibrator (Urine) Fentanyl, High Calibrator Ref# 0995	Dropper bottle: 5 mL	2/27/2026
Lin-Zhi International	LZI Fentanyl Calibrator (Urine) Fentanyl, Intermediate Calibrator Ref# 0994.	Dropper bottle: 5 mL	2/27/2026
Lin-Zhi International	LZI Fentanyl Calibrator/Control (Urine) Fentanyl, Low Calibrator/Level 1 Control Ref# 0992.	Dropper bottle: 5 mL	2/27/2026
Lin-Zhi International	LZI Fentanyl Control (Urine) Fentanyl, Level 2 Control Ref# 0998	Dropper bottle: 5 mL	2/27/2026
Lin-Zhi International	LZI Norfentanyl Calibrator (Urine), Norfentanyl, Cutoff Calibrator, Ref# 0563.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Norfentanyl Calibrator (Urine), Norfentanyl, High Calibrator, Ref# 0565.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Norfentanyl Calibrator (Urine), Norfentanyl, Intermediate Calibrator, Ref# 0564.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Norfentanyl Calibrator (Urine), Norfentanyl, Low Calibrator, Ref# 0562.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Norfentanyl Control (Urine), Norfentanyl, Level 1 Control, Ref# 0567	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Norfentanyl Control (Urine), Norfentanyl, Level 2 Control, Ref# 0568	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Opiate Calibrator (Oral Fluid) Morphine, Cutoff Calibrator Ref# S0023c.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Opiate Calibrator (Oral Fluid) Morphine, High Calibrator Ref# S0025c.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Opiate Calibrator (Oral Fluid) Morphine, Intermediate Calibrator Ref# S0024c.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Opiate Calibrator (Oral Fluid) Morphine, Low Calibrator Ref# S0022c.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Opiate Control (Oral Fluid) Morphine, Level 1 Control Ref# S0027c	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Opiate Control (Oral Fluid) Morphine, Level 2 Control Ref# S0028c	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Phencyclidine Calibrator (Oral Fluid) Phencyclidine, Cutoff Calibrator Ref# S0013c.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Phencyclidine Calibrator (Oral Fluid) Phencyclidine, High Calibrator Ref# S0015c.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Phencyclidine Calibrator (Oral Fluid) Phencyclidine, Intermediate Calibrator Ref# S0014c.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Phencyclidine Calibrator (Oral Fluid) Phencyclidine, Low Calibrator Ref# S0012c.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Phencyclidine Control (Oral Fluid) Phencyclidine, Level 1 Control Ref# S0017c.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Phencyclidine Control (Oral Fluid) Phencyclidine, Level 2 Control Ref# S0018c.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	Multi-Analyte DAU Calibrator Set E, Multi-Analyte, Cutoff Calibrator Ref# 0893.	Dropper bottle: 15 mL	3/2/2026
Lin-Zhi International	Multi-Analyte DAU Calibrator Set E, Multi-Analyte, High Calibrator Ref# 0895.	Dropper bottle: 15 mL	3/2/2026
Lin-Zhi International	Multi-Analyte DAU Calibrator Set E, Multi-Analyte, Intermediate Calibrator Ref# 0894.	Dropper bottle: 15 mL	3/2/2026
Lin-Zhi International	Multi-Analyte DAU Calibrator Set E, Multi-Analyte, Level 1 Calibrator Ref# 0897.	Dropper bottle: 15 mL	3/2/2026
Lin-Zhi International	Multi-Analyte DAU Calibrator Set E, Multi-Analyte, Level 2 Calibrator Ref# 0898.	Dropper bottle: 15 mL	3/2/2026
Lin-Zhi International	Multi-Analyte DAU Calibrator Set E, Multi-Analyte, Low Calibrator Ref# 0892.	Dropper bottle: 15 mL	3/2/2026
Lin-Zhi International	Oral Fluid 6-Acetylmorphine Calibrator 6-Acetylmorphine, Cutoff Calibrator Ref# S0293.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	Oral Fluid 6-Acetylmorphine Calibrator 6-Acetylmorphine, High Calibrator Ref# S0295.	Dropper bottle: 5 mL	2/26/2026

CHART I—Continued

Supplier name	Product name	Form	Application date
Lin-Zhi International	Oral Fluid 6-Acetylmorphine Calibrator 6-Acetylmorphine, Intermediate Calibrator Ref# S0294.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	Oral Fluid 6-Acetylmorphine Calibrator/Control 6-Acetylmorphine, Low Calibrator/Level 1 Control Ref# S0292.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	Oral Fluid 6-Acetylmorphine Control 6-Acetylmorphine, Level 2 Control Ref# S0297.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	Oral Fluid Amphetamine Calibrator Amphetamine, Cutoff Calibrator Ref# S0043b.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	Oral Fluid Amphetamine Calibrator Amphetamine, High Calibrator Ref# S0045b.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	Oral Fluid Amphetamine Calibrator Amphetamine, Intermediate Calibrator Ref# S0044b.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	Oral Fluid Amphetamine Calibrator Amphetamine, Low Calibrator Ref# S0042b.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	Oral Fluid Amphetamine Control Amphetamine, Level 1 Control Ref# S0046b.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	Oral Fluid Amphetamine Control Amphetamine, Level 2 Control Ref# S0047b.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	Oral Fluid Methamphetamine Calibrator Methamphetamine, Cutoff Calibrator Ref# S0053b.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	Oral Fluid Methamphetamine Calibrator Methamphetamine, High Calibrator Ref# S0055b.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	Oral Fluid Methamphetamine Calibrator Methamphetamine, Intermediate Calibrator Ref# S0054b.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	Oral Fluid Methamphetamine Calibrator Methamphetamine, Low Calibrator Ref# S0052b.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	Oral Fluid Methamphetamine Control Methamphetamine, Level 1 Control Ref# S0056b.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	Oral Fluid Methamphetamine Control Methamphetamine, Level 2 Control Ref# S0057b.	Dropper bottle: 5 mL	2/26/2026
Microgenics Corporation	MAS™ Omni•IMMUNE™ Control, Level 1	Glass bottle: 5 mL	1/16/2026
Microgenics Corporation	MAS™ Omni•IMMUNE™ Control, Level 2	Glass bottle: 5 mL	1/16/2026
Microgenics Corporation	MAS™ Omni•IMMUNE™ Control, Level 3	Glass bottle: 5 mL	1/16/2026
RTI International	OF26-01	HDPE vials: 3 mL	2/17/2026
RTI International	OF26-02	HDPE vials: 3 mL	2/17/2026
RTI International	OF26-03	HDPE vials: 3 mL	2/17/2026
RTI International	OF26-04	HDPE vials: 3 mL	2/17/2026
RTI International	OF26-05	HDPE vials: 3 mL	2/17/2026
RTI International	OF26-06	HDPE vials: 3 mL	2/17/2026
RTI International	OF26-07	HDPE vials: 3 mL	2/17/2026
RTI International	OF26-08	HDPE vials: 3 mL	2/17/2026
RTI International	OF26-09	HDPE vials: 3 mL	2/17/2026
RTI International	OF26-10	HDPE vials: 3 mL	2/17/2026
RTI International	OF26-11	HDPE vials: 3 mL	2/17/2026
RTI International	OF26-12	HDPE vials: 3 mL	2/17/2026
RTI International	OF26-13	HDPE vials: 3 mL	2/17/2026
RTI International	OF26-14	HDPE vials: 3 mL	2/17/2026
RTI International	OF26-15	HDPE vials: 3 mL	2/17/2026

The Assistant Administrator has found that each of the compounds, mixtures, and preparations described in Chart II, below, is not consistent with the criteria stated in 21 U.S.C. 811(g)(3)(B) and in 21 CFR 1308.23. Accordingly, the Assistant Administrator has determined that the chemical preparations or mixtures generally described in Chart II, below, and specifically described in the application materials received by DEA, are not exempt from application of any part of the CSA or from application of any part of the CFR, with regard to the requested exemption pursuant to 21 CFR 1308.23, as of the date that was provided in the determination letters to the individual requesters.

CHART II

Supplier name	Product name	Form	Application date
Lin-Zhi International	LZI Ecstasy Calibrator (Oral Fluid) MDMA, Cutoff Calibrator Ref# S0163	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Ecstasy Calibrator (Oral Fluid) MDMA, High Calibrator Ref# S0165	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Ecstasy Calibrator/Control (Oral Fluid) MDMA, Intermediate Calibrator/Level 2 Control Ref# S0168.	Dropper bottle: 5 mL	2/26/2026
Lin-Zhi International	LZI Ecstasy Calibrator/Control (Oral Fluid) MDMA, Low Calibrator/Level 1 Control Ref# S0167.	Dropper bottle: 5 mL	2/26/2026
Microgenics Corporation	1 mg/mL Phencyclidine	Kit: Glass bottles,10 mL, 50 mL, 100 mL, 250 mL.	2/16/2026
Microgenics Corporation	5 mg/mL Benzoylecgonine	Kit: Glass bottles, 5 mL,10 mL, 50 mL, 100 mL, 250 mL.	2/16/2026
Microgenics Corporation	5 mg/mL d-Methamphetamine	Kit: Glass bottles, 50 mL, 100 mL, 250 mL.	2/16/2026
Microgenics Corporation	5 mg/mL Methadone Stock	Kit: Glass bottles, 25 mL, 50 mL, 100 mL, 250 mL.	2/16/2026

CHART II—Continued

Supplier name	Product name	Form	Application date
Microgenics Corporation	5 mg/mL Morphine	Kit: Glass bottles, 50 mL, 100 mL, 250 mL, 500 mL.	2/16/2026
Microgenics Corporation	Benzoylecgonine (Cocaine) Control Stock Solution 5mg/mL	Kit: Glass bottles, 5 mL,10 mL, 50 mL, 100 mL, 250 mL.	2/16/2026
Microgenics Corporation	Methadone Control Stock Solution (5mg/mL)	Kit: Glass bottles, 25 mL, 50 mL, 100 mL, 250 mL.	2/16/2026
Microgenics Corporation	Methamphetamine (Amphetamines) Control Stock Solution (5 mg/mL)	Kit: Glass bottles, 5 mL,10 mL, 50 mL, 100 mL, 250 mL.	2/16/2026
Microgenics Corporation	Morphine (Opiate) Control Stock Solution (5 mg/mL)	Kit: Glass bottles, 10 mL, 25 mL, 50 mL, 100 mL, 250 mL, 500 mL.	2/16/2026
Microgenics Corporation	PCP Control Stock Solution (1mg/mL)	Kit: Glass bottles, 10 mL, 50 mL, 100 mL.	2/16/2026
Purisys, LLC	1 mg/mL D9-THC in methanol	Bottle: 50 g	2/25/2026
Restek Corporation	HC Δ9-THC Stock 50,000 µg/mL)	Glass ampoule: 1.3 mL	3/10/2026

Opportunity for Comment

Pursuant to 21 CFR 1308.23(e), any interested person may submit written comments on or objections to any chemical preparation in this order that has been approved or denied as exempt. If any comments or objections raise significant issues regarding any finding of fact or conclusion of law upon which this order is based, the Assistant Administrator will immediately suspend the effectiveness of any applicable part of this order until she may reconsider the application in light of the comments and objections filed. Thereafter, the Assistant Administrator shall reinstate, revoke, or amend his original order as she determines appropriate.

Approved Exempt Chemical Preparations Are Posted on DEA's Website

A list of all current exemptions, including those listed in this order, is available on DEA's website at *http://www.DEAdiversion.usdoj.gov/schedules/exempt/exempt_chemlist.pdf.* The dates of applications of all current exemptions are posted for easy reference.

Signing Authority

This document of the Drug Enforcement Administration was signed on May 14, 2026, by DEA Assistant Administrator Cheri Oz. That document with the original signature and date is maintained by DEA. For administrative purposes only, and in compliance with requirements of the Office of the Federal Register, the undersigned DEA Federal Register Liaison Officer has been authorized to sign and submit the document in electronic format for publication, as an official document of DEA. This administrative process in no way alters the legal effect of this document upon publication in the **Federal Register**.

Heather Achbach,

Federal Register Liaison Officer, Drug Enforcement Administration.

[FR Doc. 2026–10090 Filed 5–19–26; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

[OMB Number 1123–0NEW]

Agency Information Collection Activities; Proposed eCollection eComments Requested; New Collection: Title—Corporate Whistleblower Awards Pilot Program Online Intake Portal

AGENCY: Criminal Division, Department of Justice.

ACTION: 30-Day notice.

SUMMARY: The Criminal Division, Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.

DATES: Comments are encouraged and will be accepted for 30 days until June 22, 2026.

FOR FURTHER INFORMATION CONTACT: If you have comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact: Patrick Gushue, 1499 New York Ave. NW, Washington, DC 20005, phone: (202) 578–5219 or email: *patrick.gushue@usdoj.gov.*

SUPPLEMENTARY INFORMATION: The proposed information collection was previously published in the **Federal Register** on March 4, 2026, 91 FR 10633, allowing a 60-day comment period. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

—Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

—Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

—Enhance the quality, utility, and clarity of the information to be collected; and/or

—Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.,* permitting electronic submission of responses.

Written comments and recommendations for this information collection should be submitted within 30 days of the publication of this notice on the following website *www.reginfo.gov/public/do/PRAMain.* Find this particular information collection by selecting ''Currently under 30-day Review—Open for Public Comments'' or by using the search function and entering either the title of the information collection or the OMB Control Number. This information collection request may be viewed at *www.reginfo.gov.* Follow the instructions to view Department of Justice, information collections currently under review by OMB.

DOJ seeks PRA authorization for this information collection for three (3) years. OMB authorization for an ICR cannot be for more than three (3) years